LifeMD
LifeMD's revenue rose 25.3% to $194 million in fiscal 2025. Its operating margin was −4.0%, up from −13.2% a year earlier. Free cash flow was $6 million, down 60.1%. It paid out $3 million in dividends and buybacks, 53% of free cash flow. The diluted share count rose 9.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 41 | 4 | 33 | 35 | 37 |
| Debt incl. finance leases | — | — | 18 | 18 | — |
| Net debt (negative means net cash) | — | — | −15 | −17 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 5.2x | — | — |
| Interest coverage | −18.0x | −34.0x | −5.6x | −9.4x | −5.6x |
| Current ratio | 2.0x | 0.4x | 1.2x | 0.8x | 1.2x |
| Quick ratio | 1.9x | 0.2x | 1.1x | 0.7x | 1.2x |
Cash flow
Projections
Project LifeMD's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What LifeMD says to expect
- Fourth quarter 2026: revenue and adjusted EBITDA
For the fourth quarter of 2026, the Company expects: ● Revenue in the range of $46 million to $49 million. ● Adjusted EBITDA in the range of negative $4 million to negative $2 million.
- Full year 2026: revenue and adjusted EBITDA
For the full year 2026, the Company expects (revised from previous guidance): ● Revenue in the range of $188 million to $191 million, compared with previous guidance of $205.5 million to $212.5 million. ● Adjusted EBITDA in the range of negative $12.6 million to negative $10.6 million, compared with previous guidance of negative $6.0 million to breakeven.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought LifeMD shares on the open market, and 1 insider sold $54,150.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 9, 2025 | Jessica FriedemanChief Marketing Officer | Sold | 15,000 | $3.61 | $54,150 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 4 of 9 | — |
| Rule of 40 | 33.8% | 11.9% | 28.6% |
| Altman Z'' | −12.65 | −13.47 | −9.85 |
| Accruals ratio | −69.9% | −57.8% | 8.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | Pass | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | 4 of 9 | — |
Compare
Put LifeMD side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| LifeMD | FY25 | 25.3% | −4.0% | 3.3% | — | — | — | |
| biote | FY25 | −2.5% | 18.5% | 15.7% | — | 2.0x | 5 | Compare |
| Strata Critical Medical | FY25 | 34.3% | −11.3% | −29.7% | −11.3% | — | 4 | Compare |
| SBC Medical Group | FY25 | −15.5% | 38.9% | 13.4% | 38.4% | −1.7x | 4 | Compare |
| AirSculpt Technologies | FY25 | −15.8% | −7.6% | 0.5% | −6.6% | 39.0x | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 5 | 4 | 8 | 12 | 37 | 93 | 119 | 152 | 155 | 194 |
| Revenue growth | 329.8% | −29.7% | 126.1% | 49.8% | 199.1% | 149.0% | 28.2% | 28.1% | 1.5% | 25.3% |
| Gross profit | 3 | 3 | 6 | 10 | 28 | 75 | 100 | 134 | 133 | 166 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | −1 | −1 | −2 | −3 | −58 | −54 | −43 | −14 | −20 | −8 |
| Net income | −1 | −1 | −1 | −3 | −59 | −61 | −46 | −21 | −21 | 14 |
| Diluted EPS (US$) | −0.15 | −0.15 | −0.25 | −0.32 | −4.44 | −2.29 | −1.57 | −0.70 | −0.60 | 0.25 |
| Diluted shares (millions) | 7 | 8 | 9 | 10 | 14 | 27 | 31 | 34 | 41 | 45 |
| Cash flow | ||||||||||
| Cash from operations | −0 | −1 | −1 | 0 | −12 | −33 | −23 | 9 | 18 | 8 |
| Capital expenditure | — | — | — | — | — | 0 | 0 | 0 | 2 | 2 |
| Free cash flow | — | — | — | — | — | −33 | −23 | 9 | 16 | 6 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 3 | 3 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 0 | 0 | 1 | 19 | 12 | 14 | 12 | 12 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 0 | 0 | 0 | 1 | 9 | 41 | 4 | 33 | 35 | 37 |
| Debt incl. finance leases | — | 0 | 0 | — | — | — | — | 18 | 18 | — |
| Total assets | 1 | 1 | 3 | 3 | 13 | 50 | 26 | 58 | 76 | 70 |
| Total liabilities | 1 | 1 | 2 | 5 | 14 | 24 | 33 | 53 | 84 | 47 |
| Shareholders' equity | −0 | 1 | 1 | −1 | −2 | 23 | −11 | 4 | −9 | 23 |
| Margins and ratios | ||||||||||
| Gross margin | 62.9% | 72.3% | 76.0% | 79.8% | 76.2% | 80.6% | 84.3% | 87.6% | 86.2% | 85.7% |
| Operating margin | −22.4% | −33.4% | −24.7% | −23.2% | −155.0% | −58.5% | −36.5% | −9.5% | −13.2% | −4.0% |
| Net margin | −21.1% | −32.8% | −14.9% | −25.2% | −157.3% | −65.6% | −38.2% | −13.5% | −13.8% | 7.4% |
| Free cash flow margin | — | — | — | — | — | −35.9% | −19.6% | 5.7% | 10.4% | 3.3% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | 113.2% | 8.6% | 33.8% | 11.9% | 28.6% |
| Return on capital | — | — | −166.5% | — | — | — | — | — | — | — |
| Return on equity | — | −457.9% | −139.4% | — | — | −595.9% | −802.8% | — | — | 204.0% |
| Return on assets | −178.9% | −117.5% | −64.0% | −103.5% | −696.1% | −192.3% | −120.5% | −49.0% | −31.8% | 19.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |